Table 1 Strategies and mechanisms of reversing drug resistance by inducing ferroptosis
From: Ferroptosis in cancer therapy: a novel approach to reversing drug resistance
Reversing chemotherapy resistance by inducing ferroptosis. | |||||
Chemotherapeutic Drugs | Ferroptosis-Inducing Compounds | Targets for Ferroptosis Induction | Cancer Type | Mechanisms | References |
Temozolomide | Curcumin analog | Glutathione peroxidase 4 (GPX4) | Glioblastoma | Curcumin analog induces androgen receptor (AR) ubiquitination and suppresses GPX4, thereby inducing ferroptosis and overcoming temozolomide resistance. | [33] |
Oxaliplatin | / | GPX4 | Colorectal cancer | Disrupting the KIF20A/NUAK1/PP1β/GPX4 pathway inhibits GPX4 to induce ferroptosis and overcomes oxaliplatin resistance. | [34] |
Cisplatin | Ent-kaurane diterpenoids | Glutathione (GSH) | Lung cancer | Ent-kaurane diterpenoids target peroxiredoxin I/II and block GSH synthesis, thereby inducing ferroptosis and overcoming cisplatin resistance. | [35] |
Erastin and sulfasalazine | Cystine/glutamate antiporter (xCT) | Head and neck cancer | Erastin and sulfasalazine inhibit the xCT system to induce ferroptosis and overcome cisplatin resistance. | [36] | |
/ | xCT | Gastric cancer | Suppressing the Nrf2/Keap1/xCT pathway inhibits xCT system to induce ferroptosis and overcome cisplatin resistance. | [37] | |
Dihydroartemisinin | Labile iron pool (LIP) | Pancreatic ductal adenocarcinoma | Dihydroartemisinin increases cellular LIP to induce ferroptosis and overcome cisplatin resistance. | [38] | |
5-fluorouracil | / | Lipocalin 2 (LCN2) | Colorectal cancer | Targeting LCN2 increases cellular LIP to induce ferroptosis and overcome 5-fluorouracil resistance. | |
Multidrugs | / | Divalent metal transporter 1 (DMT1) | Breast cancer | Inhibition of DMT1 increases cellular LIP to induce ferroptosis and overcome multidrug resistance. | [41] |
Reversing targeted therapy resistance by inducing ferroptosis. | |||||
Targeted Drugs | Ferroptosis-Inducing Compounds | Targets for Ferroptosis Induction | Cancer Type | Mechanisms | References |
Olaparib | Sulfasalazine | xCT | Â Ovarian cancer | Sulfasalazine suppresses SLC7A11 to induce ferroptosis and overcome olaparib resistance. | [42] |
Cetuximab | β-elemene | GPX4 | Colorectal cancer (KRAS-mutant) | β-elemene inhibits GPX4 to induce ferroptosis and overcome cetuximab resistance. | [43] |
Gefitinib | / | GPX4 | Breast cancer | Inhibition of GPX4 induces ferroptosis and overcomes gefitinib resistance. | [44] |
Sorafenib | Trigonelline | NRF2 | Hepatocellular carcinoma | Trigonelline inhibits NRF2 to induce ferroptosis and overcome sorafenib resistance. | [45] |
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) | Vorinostat | xCT | Lung cancer | Vorinostat inhibits xCT system to induce ferroptosis and overcome EGFR-TKIs resistance. | [46] |
Sunitinib | Artesunate | GPX4 | Renal cell carcinoma | Artesunate inhibits GPX4 to induce ferroptosis and overcome sunitinib resistance. | [47] |